|
|
|
|
|
|
|
|
|
|
|
|
|
S.B. 333 VETOES
|
|
|
|
|
|
|
|
|
(12) (13) TWO MARYLAND CITIZENS WHO REPRESENT THE PERSPECTIVE
OF PAIN PATIENTS, APPOINTED BY THE SECRETARY FROM A LIST SUBMITTED BY THE
MARYLAND PAIN INITIATIVE.
(C) THE SECRETARY SHALL DESIGNATE THE CHAIR OF THE BOARD.
(D) (1) THE TERM OF A MEMBER APPOINTED BY THE SECRETARY IS 3 YEARS.
(2) IF A VACANCY OCCURS DURING THE TERM OF AN APPOINTED
MEMBER, THE SECRETARY SHALL APPOINT A SUCCESSOR WHO SHALL SERVE UNTIL
THE TERM EXPIRES.
(E) THE BOARD SHALL:
(1) MEET NOT FEWER THAN THREE TIMES ANNUALLY;
(2) MAKE RECOMMENDATIONS TO THE SECRETARY REGARDING THE
DESIGN AND IMPLEMENTATION OF A PRESCRIPTION MONITORING PROGRAM, IN
ACCORDANCE WITH THE PROVISIONS OF THIS SUBTITLE, INCLUDING
RECOMMENDATIONS ABOUT:
(I) REGULATIONS AND THE NEED FOR ANY FURTHER
LEGISLATION CONCERNING THE PROGRAM; AND
(II) SOURCES OF FUNDING, INCLUDING GRANT FUNDS UNDER THE
HAROLD ROGERS PRESCRIPTION DRUG MONITORING PROGRAM AND OTHER
FEDERAL OR STATE PROGRAMS, WITH THE OBJECTIVE OF AVOIDING ANY FEE OR
ASSESSMENT AGAINST DISPENSERS OR PRESCRIBERS SOURCES OF FEDERAL,
PRIVATE, OR STATE FUNDS;
(3) (I) PROVIDE WITHIN 180 DAYS AFTER ITS FIRST MEETING, IN
ACCORDANCE WITH § 2-1246 OF THE STATE GOVERNMENT ARTICLE, AN INTERIM
REPORT TO THE GENERAL ASSEMBLY SETTING FORTH THE BOARD'S ANALYSIS AND
RECOMMENDATIONS UNDER ITEM (2) OF THIS SUBSECTION REGARDING THE
DESIGN, IMPLEMENTATION, AND FUNDING OF THE PROGRAM; AND
(II) PROVIDE ANNUALLY TO THE GOVERNOR AND, IN ACCORDANCE
WITH § 2-1246 OF THE STATE GOVERNMENT ARTICLE, THE GENERAL ASSEMBLY AN
ANALYSIS OF THE IMPACT OF THE PROGRAM ON PATIENT ACCESS TO
PHARMACEUTICAL CARE AND ON CURBING PRESCRIPTION DRUG DIVERSION IN THE
STATE, INCLUDING ANY RECOMMENDATIONS RELATED TO MODIFICATION OR
CONTINUATION OF THE PROGRAM; AND
(4) PROVIDE ONGOING ADVICE AND CONSULTATION ON THE
IMPLEMENTATION AND OPERATION OF THE PROGRAM, INCLUDING
RECOMMENDATIONS REGARDING:
(I) CHANGES IN THE PROGRAM TO REFLECT ADVANCES IN
TECHNOLOGY AND BEST PRACTICES IN THE FIELD OF ELECTRONIC HEALTH
RECORDS AND ELECTRONIC PRESCRIPTION MONITORING; AND
(II) EMERGING DRUGS OF CONCERN THAT SHOULD BE IDENTIFIED
AS MONITORED PRESCRIPTION DRUGS; AND
- 3026 -
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
